Highlights

  • ReNerve lifts quarterly sales to AUD 0.584mn.
  • Revenue increases 774% YoY and 176% QoQ.
  • The company secures Indonesian marketing approval for its nerve cuff.
  • ReNerve draws the first tranche of a staged funding facility.

ReNerve (ASX:RNV), an Australian biotechnology company developing products for peripheral nerve injury repair, has delivered its strongest sales quarter as commercial activity expands across several markets. Sales in 1QFY27 exceeded the entire previous financial year's result, while Indonesian approval and first procedures in Hong Kong and Malaysia extended the reach of its NervAlign Nerve Cuff.

Sales Pass a New Quarterly Mark

Sales reached AUD 0.584mn in the three months ended 30 September 2026, increasing 774% YoY and 176% QoQ. September also became the company's first month with sales above AUD 0.2mn. Customer cash receipts totalled AUD 0.419mn.

The company links the sales progress to multiple product ranges, direct salespeople, its network of 25 US distributors and marketing activity in Asia. The quarter therefore combined rising sales with broader commercial access, as ReNerve continued work on product expansion and market initiatives.

Asian Approvals Move into Clinical Use

Marketing approval for the NervAlign Nerve Cuff in Indonesia arrived in July. It provides a pathway to introduce the product through local partners to clinicians and patients in that market.

In September, ReNerve completed the first nerve-cuff cases in Hong Kong and Malaysia. Those procedures followed earlier regulatory and distribution progress and marked initial clinical use in both markets. The milestones form part of the company's Asia-Pacific commercialisation strategy, alongside its existing US distribution activity and direct selling efforts.

Staged Financing Supports Commercialisation

ReNerve secured a convertible-note facility of up to AUD 5mn, available in stages over three years for commercialisation, working capital and general corporate purposes. The initial drawdown had a face value of approximately AUD 1.6mn.

After the issue discount, drawdown fee and legal costs, that drawdown provided approximately AUD 1.361mn in net cash proceeds. The facility carries first-ranking security over present and future property, including future research and development tax-incentive proceeds. Quarter-end cash was approximately AUD 1.62mn, following the initial funding drawdown during the period.

Research Continues Alongside the Rollout

The company is participating in an Australian Government-funded AUD 0.499mn project investigating a gel made from a patient's own blood to support nerve regeneration after prostate surgery. The research may also have applications involving nerve cuffs, wraps, conduits and the Nerve Guide Matrix, but remains at the research and development stage.

Quarterly research and development cash spending fell to AUD 0.165mn from AUD 0.752mn in the preceding quarter. Product manufacturing and operating activities generated AUD 0.046mn net cash inflow, while overall operating activities used approximately AUD 1.11mn. Related-party payments totalled AUD 0.199mn for director fees, salaries and associated payroll costs. The full AUD 7mn prospectus allocation had been applied by quarter-end across development, studies, listing costs and working capital.